Top

Published in:

Open Access 01-10-2020 | Original Article

Evaluation of a screening program for iron overload andHFE mutations in 50,493 blood donors

Authors: Carl Eckerström, Sofia Frändberg, Lena Lyxe, Cecilia Pardi, Jan Konar

Published in: Annals of Hematology | Issue 10/2020

Abstract

Early detection of individuals with hereditary hemochromatosis (HH) is important to manage iron levels and prevent future organ damage. Although theHFE mutations that cause most cases of HH have been identified, their geographic distribution is highly variable, and their contribution to iron overload is not fully understood. All new registered blood donors at the Sahlgrenska University hospital between 1998 and 2015 were included in the study. Donors with signs of iron overload at baseline and subsequent follow-up testing were recommended genotyping of the HFE gene. Of the 50,493 donors that were included in the study, 950 (1.9%) had signs of iron overload on both test occasions. Of the 840 donors with iron overload that performed HFE genotyping, 117 were homozygous for C282Y, and 97 were compound heterozygotes. The prevalence of C282Y homozygosity was 0.23%. Iron overload screening effectively detects individuals at risk of carrying the C282Y mutation of the HFE gene and enables early treatment to prevent HH complications.

Salgia RJ, Brown K (2015) Diagnosis and management of hereditary hemochromatosis. Clin Liver Dis 19(1):187–198. https://doi.org/10.1016/j.cld.2014.09.011CrossRefPubMed

Powell LW, Seckington RC, Deugnier Y (2016) Haemochromatosis. Lancet 388(10045):706–716. https://doi.org/10.1016/S0140-6736(15)01315-XCrossRefPubMed

European Association For The Study Of The L (2010) EASL clinical practice guidelines for HFE hemochromatosis. J Hepatol 53(1):3–22. https://doi.org/10.1016/j.jhep.2010.03.001CrossRef

Allen KJ, Gurrin LC, Constantine CC, Osborne NJ, Delatycki MB, Nicoll AJ, McLaren CE, Bahlo M, Nisselle AE, Vulpe CD, Anderson GJ, Southey MC, Giles GG, English DR, Hopper JL, Olynyk JK, Powell LW, Gertig DM (2008) Iron-overload-related disease in HFE hereditary hemochromatosis. N Engl J Med 358(3):221–230. https://doi.org/10.1056/NEJMoa073286CrossRefPubMed

Pedersen P, Milman N (2009) Genetic screening for HFE hemochromatosis in 6,020 Danish men: penetrance of C282Y, H63D, and S65C variants. Ann Hematol 88(8):775–784. https://doi.org/10.1007/s00277-008-0679-1CrossRefPubMed

Thorstensen K, Kvitland MA, Irgens WO, Hveem K, Asberg A (2010) Screening for C282Y homozygosity in a Norwegian population (HUNT2): the sensitivity and specificity of transferrin saturation. Scand J Clin Lab Invest 70(2):92–97. https://doi.org/10.3109/00365510903527838CrossRefPubMed

Deugnier Y, Jouanolle AM, Chaperon J, Moirand R, Pithois C, Meyer JF, Pouchard M, Lafraise B, Brigand A, Caserio-Schoenemann C, Mosser J, Adams P, Le Gall JY, David V (2002) Gender-specific phenotypic expression and screening strategies in C282Y-linked haemochromatosis: a study of 9396 French people. Br J Haematol 118(4):1170–1178. https://doi.org/10.1046/j.1365-2141.2002.03718.xCrossRefPubMed

Aleman S, Endalib S, Stal P, Loof L, Lindgren S, Sandberg-Gertzen H, Almer S, Olsson S, Danielsson A, Wallerstedt S, Hultcrantz R (2011) Health check-ups and family screening allow detection of hereditary hemochromatosis with less advanced liver fibrosis and survival comparable with the general population. Scand J Gastroenterol 46(9):1118–1126. https://doi.org/10.3109/00365521.2011.591426CrossRefPubMed

Asberg A, Hveem K, Thorstensen K, Ellekjter E, Kannelonning K, Fjosne U, Halvorsen TB, Smethurst HB, Sagen E, Bjerve KS (2001) Screening for hemochromatosis: high prevalence and low morbidity in an unselected population of 65,238 persons. Scand J Gastroenterol 36(10):1108–1115CrossRef

10.

de Graaff B, Neil A, Si L, Yee KC, Sanderson K, Gurrin L, Palmer AJ (2017) Cost-effectiveness of different population screening strategies for hereditary haemochromatosis in Australia. Appl Health Econ Health Policy 15(4):521–534. https://doi.org/10.1007/s40258-016-0297-3CrossRefPubMed

11.

Barton JC, Acton RT, Lovato L, Speechley MR, CE ML, Harris EL, Reboussin DM, Adams PC, Dawkins FW, Gordeuk VR, Walker AP, Hemochromatosis, Iron Overload Screening Study Research I (2006) Initial screening transferrin saturation values, serum ferritin concentrations, and HFE genotypes in native Americans and whites in the hemochromatosis and iron overload screening study. Clin Genet 69(1):48–57. https://doi.org/10.1111/j.1399-0004.2006.00553.xCrossRefPubMed

12.

Merryweather-Clarke AT, Pointon JJ, Jouanolle AM, Rochette J, Robson KJ (2000) Geography of HFE C282Y and H63D mutations. Genet Test 4(2):183–198. https://doi.org/10.1089/10906570050114902CrossRefPubMed

13.

Steinberg KK, Cogswell ME, Chang JC, Caudill SP, McQuillan GM, Bowman BA, Grummer-Strawn LM, Sampson EJ, Khoury MJ, Gallagher ML (2001) Prevalence of C282Y and H63D mutations in the hemochromatosis (HFE) gene in the United States. JAMA 285(17):2216–2222. https://doi.org/10.1001/jama.285.17.2216CrossRefPubMed

14.

Jackson HA, Carter K, Darke C, Guttridge MG, Ravine D, Hutton RD, Napier JA, Worwood M (2001) HFE mutations, iron deficiency and overload in 10,500 blood donors. Br J Haematol 114(2):474–484. https://doi.org/10.1046/j.1365-2141.2001.02949.xCrossRefPubMed

15.

O'Toole R, Romeril K, Bromhead C (2017) Using iron studies to predict HFE mutations in New Zealand: implications for laboratory testing. Intern Med J 47(4):447–454. https://doi.org/10.1111/imj.13360CrossRefPubMed

16.

Adams P, Altes A, Brissot P, Butzeck B, Cabantchik I, Cancado R, Distante S, Evans P, Evans R, Ganz T, Girelli D, Hultcrantz R, McLaren G, Marris B, Milman N, Nemeth E, Nielsen P, Pineau B, Piperno A, Porto G, Prince D, Ryan J, Sanchez M, Santos P, Swinkels D, Teixeira E, Toska K, Vanclooster A, White D, Contributors, Hemochromatosis International T (2018) Therapeutic recommendations in HFE hemochromatosis for p.Cys282Tyr (C282Y/C282Y) homozygous genotype. Hepatol Int 12(2):83–86. https://doi.org/10.1007/s12072-018-9855-0CrossRefPubMedPubMedCentral

17.

Allen KJ, Bertalli NA, Osborne NJ, Constantine CC, Delatycki MB, Nisselle AE, Nicoll AJ, Gertig DM, CE ML, Giles GG, Hopper JL, Anderson GJ, Olynyk JK, Powell LW, Gurrin LC, HealthIron Study I (2010) HFE Cys282Tyr homozygotes with serum ferritin concentrations below 1000 microg/L are at low risk of hemochromatosis. Hepatology 52(3):925–933. https://doi.org/10.1002/hep.23786CrossRefPubMedPubMedCentral

18.

Lanktree MB, Lanktree BB, Pare G, Waye JS, Sadikovic B, Crowther MA (2015) Examining the clinical use of hemochromatosis genetic testing. Can J Gastroenterol Hepatol 29(1):41–45CrossRef

19.

Burke W, Imperatore G, McDonnell SM, Baron RC, Khoury MJ (2000) Contribution of different HFE genotypes to iron overload disease: a pooled analysis. Genet Med 2(5):271–277. https://doi.org/10.1097/00125817-200009000-00001CrossRefPubMed

20.

Aguilar-Martinez P, Grandchamp B, Cunat S, Cadet E, Blanc F, Nourrit M, Lassoued K, Schved JF, Rochette J (2011) Iron overload in HFE C282Y heterozygotes at first genetic testing: a strategy for identifying rare HFE variants. Haematologica 96(4):507–514. https://doi.org/10.3324/haematol.2010.029751CrossRefPubMedPubMedCentral

21.

Laursen AH, Bjerrum OW, Friis-Hansen L, Hansen TO, Marott JL, Magnussen K (2018) Causes of iron overload in blood donors - a clinical study. Vox Sang 113(2):110–119. https://doi.org/10.1111/vox.12619CrossRefPubMed

22.

Guillygomarc'h A, Christian J, Romain M, Vincent Q, Veronique D, Deugnier Y (2003) Circadian variations of transferrin saturation levels in iron-overloaded patients: implications for the screening of C282Y-linked haemochromatosis. Br J Haematol 120(2):359–363. https://doi.org/10.1046/j.1365-2141.2003.04070.xCrossRefPubMed

Title: Evaluation of a screening program for iron overload andHFE mutations in 50,493 blood donors
Authors: Carl Eckerström
Sofia Frändberg
Lena Lyxe
Cecilia Pardi
Jan Konar
Publication date: 01-10-2020
Publisher: Springer Berlin Heidelberg
Published in: Annals of Hematology / Issue 10/2020
Print ISSN: 0939-5555
Electronic ISSN: 1432-0584
DOI: https://doi.org/10.1007/s00277-020-04146-8

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Evaluation of a screening program for iron overload andHFE mutations in 50,493 blood donors

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 10/2020

Low-dose lenalidomide and dexamethasone therapy after melphalan-prednisolone induction in elderly patients with newly diagnosed multiple myeloma

Allogeneic stem cell transplantation mitigates the adverse prognostic impact of high diagnostic BAALC and MN1 expression in AML

The prognostic value of 25-hydroxy vitamin D deficiency and its interaction with c-Myc expression in diffuse large B cell lymphoma

Effect of lubiprostone on vinca alkaloid–induced constipation in patients with hematological malignancies: a propensity score–matched analysis

Germinotropic lymphoproliferative disorder: a systematic review

LPL deletion is associated with poorer response to ibrutinib-based treatments and overall survival in TP53-deleted chronic lymphocytic leukemia

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page